Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Phase II Pilot Study of TPF (Docetaxel, Cisplatin, and 5-FU) Induction Chemotherapy Followed by Concurrent Cisplatin and Reduced Dose Radiation in Locally Advanced Head and Neck Cancer

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00352118

Enrollment

Registered

2006-07-14

Start date

2006-03-31

Completion date

2008-04-30

Last updated

2017-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Keywords

oral complications of radiation therapy, oral complications of chemotherapy, mucositis, xerostomia, stage III squamous cell carcinoma of the hypopharynx, stage IV squamous cell carcinoma of the hypopharynx, stage III squamous cell carcinoma of the larynx, stage IV squamous cell carcinoma of the larynx, stage III squamous cell carcinoma of the lip and oral cavity, stage IV squamous cell carcinoma of the lip and oral cavity, stage III squamous cell carcinoma of the oropharynx, stage IV squamous cell carcinoma of the oropharynx

Brief summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with radiation therapy works in treating patients with locally advanced head and neck cancer. The doctor also wants to find out if patients who receive this treatment need a feeding tube 1 year after starting treatment.

Detailed description

OBJECTIVES: Primary * Determine feeding tube dependency at 12 months in patients with locally advanced head and neck cancer treated with induction chemotherapy comprising docetaxel, cisplatin, and fluorouracil followed by cisplatin and reduced-dose radiotherapy. Secondary * Determine the progression-free, disease-free, and overall survival of patients treated with this regimen. * Determine the pattern of failure in patients treated with this regimen. * Evaluate the quality of life of patients treated with this regimen. * Assess pre- and post-treatment swallowing ability of patients and the impact on their quality of life. Tertiary * Quantify salivary flow rates of patients receiving chemotherapy with radiotherapy for head and neck malignancy. * Evaluate the quality of saliva by examining total protein concentrations. * Quantify proangiogenic cytokines (interleukin \[IL\]-1, IL-6, IL-8, and vascular endothelial growth factor) in the saliva of these patients. * Determine the degree of mucositis and xerostomia of patients receiving chemotherapy with radiotherapy for head and neck malignancy. * Compare salivary flow rates with the grade of mucositis and xerostomia of patients receiving chemotherapy with radiotherapy for head and neck malignancy. OUTLINE: This is a pilot study. * Induction therapy: Patients receive docetaxel IV over 1 hour and cisplatin IV over 1 hour on day 1 followed by fluorouracil IV continuously on days 1- 4. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 5-14 or pegfilgrastim SC on day 5. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a partial or clinical complete response proceed to chemoradiotherapy 3 weeks later. * Chemoradiotherapy: Patients receive cisplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo concurrent reduced-dose radiotherapy 5 days a week for 6 weeks. * Surgery: Approximately 6 to 8 weeks after completing chemoradiotherapy, patients with residual neck disease or disease initially staged at N2 or greater undergo neck dissection. Saliva is collected periodically to measure flow rates and quality; quantify proangiogenic cytokines (interleukin \[IL\]-1, IL-6, IL-8 and vascular endothelial growth factor); and examine the grade of mucositis and xerostomia. Quality of life is assessed at baseline, before chemoradiotherapy, 1 month after the last radiation treatment, every 3 months for 1 year, and then every 6 months for 1 year. After completion of study treatment, patients are followed periodically for 5 years and then annually thereafter. PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.

Interventions

BIOLOGICALfilgrastim

subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.

BIOLOGICALpegfilgrastim

If applicable on day 5, repeating every 3 weeks for 2 courses.

DRUGcisplatin

Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.

DRUGdocetaxel

Intravenous over 1 hour on day 1.

DRUGfluorouracil

Intravenous continuously on days 1-4.

PROCEDUREconventional surgery

As appropriate, neck dissection.

RADIATIONradiation therapy

60 Gy 5 days/week x 6 weeks with cisplatin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically confirmed squamous cell carcinoma of the head and neck * Stage IVA or IVB disease * Stage III disease allowed provided patient may benefit from organ preservation or patient refused surgery * Measurable or evaluable disease * ECOG performance status 0-2 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Creatinine ≤ 1.5 mg/dL OR glomerular filtration rate ≥ 60 mL/min * Bilirubin normal * Alkaline phosphatase (AP) and AST or ALT must be within the following ranges: * AP normal AND AST or ALT ≤ 5 times upper limit of normal (ULN) * AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN * AP ≤ 5 times ULN AND AST or ALT normal

Exclusion criteria

* Salivary gland, sinus, or nasopharyngeal primary disease * Evidence of distant metastatic disease * Pregnant or nursing * Positive pregnancy test (Fertile patients must use effective contraception during study treatment and for 3 months after completion of study treatment) * Other malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other malignancy in which stage and nature of disease is such that it is unlikely to affect survival for the next 3 years * Peripheral neuropathy ≥ grade 2 * Hearing loss ≥ grade 2 * Severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 and/or cisplatin or other platinum analogs * Poor nutritional status, in the opinion of the investigator * Active infection * Active ischemic heart disease * Myocardial infarction within the past 6 months * Prior radiotherapy above the clavicles * Prior chemotherapy * Prior surgery to the primary tumor except biopsy * Concurrent amifostine or other investigational agents

Design outcomes

Primary

Measure	Time frame	Description
Number of Patients With Feeding Tube Dependency	at 12 months	All patients were non-evaluable and study was terminated early. There is no measure of outcome.

Secondary

Measure	Time frame	Description
Number of Days - Overall Survival	Between date of registration to date of death.	All patients were non-evaluable and study was terminated early. There is no measure of outcome. Utilizing RECIST criteria.
Number of Days With Disease Free Survival	From Date of Registration to Date of First Treatment Failure or Death	All patients were non-evaluable and study was terminated early. There is no measure of outcome. RECIST criteria measurement.
Number of Days With Progression-free Survival	Between date of registration to date of first treatment failure or death.	All patients were non-evaluable and study was terminated early. There is no measure of outcome. Utilizing RECIST criteria.
Time to Treatment Failure	Number of Days from Complete or Partial Response to First Date of Recurrence or Progression	All patients were non-evaluable and study was terminated early. There is no measure of outcome. Measure using RECIST criteria.
Swallowing Ability - Quality of Life Scores	Baseline, before chemoradiation, 30 days after last radiation treatment, every 3 months for the first year, then every 6 months for year 2.	All patients were non-evaluable and study was terminated early. There is no measure of outcome. Utilizing Swallowing Portion of ASHA Functional Communication Measure for Swallowing (FCM) and Dysphagia Outcome and Severity Scale (DOSS).
Quality of Life (QOL) by Functional Assessment of Cancer Therapy-H&N QOL Questionnaire	baseline, before chemoradiotherapy, 1 month after the last radiation treatment, every 3 months for 1 year, and then every 6 months for 1 year	All patients were non-evaluable and study was terminated early. There is no measure of outcome.

Countries

United States

Participant flow

Recruitment details

Patients were recruited from the Masonic Cancer Center physicians' clinics.

Participants by arm

Arm	Count
Chemotherapy + Low Dose Radiation Patients receiving combination chemotherapy plus low dose radiation	4
Total	4

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Physician Decision	4

Baseline characteristics

Characteristic	Chemotherapy + Low Dose Radiation
Age, Categorical <=18 years	0 Participants
Age, Categorical >=65 years	2 Participants
Age, Categorical Between 18 and 65 years	2 Participants
Age, Continuous	62.8 years STANDARD_DEVIATION 7.4
Region of Enrollment United States	4 participants
Sex: Female, Male Female	1 Participants
Sex: Female, Male Male	3 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	0 / 4
serious Total, serious adverse events	0 / 4

Outcome results

Primary